Teleflex Incorporated (TFX) Stock

Teleflex Incorporated (TFX) is a Healthcare stock trading at $134.99 (as of 2026-08-20), with a market capitalization of $5.98B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Teleflex designs, develops, manufactures, and supplies medical devices used in diagnostic and therapeutic procedures, including vascular access tools (such as catheters and related navigation/closure products), interventional cardiology and peripheral products, anesthesia solutions, and surgical devices. Its offerings are used by healthcare providers such as interventional cardiologists, radiologists, vascular surgeons, and hospitals, including emergency medicine and military channels.

Understand Teleflex Incorporated: how it makes money

Teleflex designs and supplies single-use medical devices, including vascular access catheters and interventional coronary catheters, and makes money by selling these products used during diagnostic and therapeutic procedures in critical care and surgical settings worldwide.

The profit engine is procedure-based demand for single-use devices, with revenue tied to clinical use of vascular access products and interventional catheters rather than longer life-cycle capital equipment.

Business quality (Weak): Clear business focus on single-use medical devices (vascular access and interventional products), but the provided data does not give a clean, mutually exclusive segment split that sums to the stated total revenue.

Bull case

  • Broad critical care and surgical device offering: Products span vascular access (including Arrow branded catheters and catheter navigation and tip positioning systems) and interventional products (including coronary catheters).
  • High gross margin profile: Gross margin is reported at 56.1% for the latest period, which can support profitability if operating expenses are controlled.

Bear case

  • Thin operating margin: Operating margin is reported at 3.7% for the latest period, so earnings can be sensitive to changes in operating costs.
  • Demand depends on clinical procedure usage: Because the devices are used for diagnostic and therapeutic procedures in critical care and surgical applications, revenue can be affected by procedure volumes and related usage patterns.
Valuation — source: SEC EDGAR (first-party)
Price$134.99
Market Cap$5.98B
Price / Book2.06
Price / Sales2.32
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1.99B
Net Margin-45.4%
Revenue Growth (YoY)-34.6%
EPS Growth (YoY)-1462.4%
Financial Health — source: SEC EDGAR
Altman Z-Score2.12 (grey)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($644.94M)
Institutional Holders Tracked10
Congressional Trades (recent)10
Company
SectorHealthcare
IndustryMedical Equipment
CEOStuart A. Randle
Employees14,100
CountryUS
IPO Date1980-03-17

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Glaukos Corporation (GKOS)
  • Insulet Corporation (PODD)
  • MiniMed Group, Inc. (MMED)
  • Merit Medical Systems, Inc. (MMSI)
  • Haemonetics Corporation (HAE)
  • ICU Medical, Inc. (ICUI)
  • iRhythm Technologies, Inc. (IRTC)
  • Heartflow, Inc. Common Stock (HTFL)
TFX earnings history · TFX institutional & insider holders · TFX KPIs & operating metrics · TFX financials · TFX investor presentations & press releases · TFX SEC filings · TFX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.